These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 21816315)

  • 1. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
    Bisognano JD; Bakris G; Nadim MK; Sanchez L; Kroon AA; Schafer J; de Leeuw PW; Sica DA
    J Am Coll Cardiol; 2011 Aug; 58(7):765-73. PubMed ID: 21816315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.
    Bakris GL; Nadim MK; Haller H; Lovett EG; Schafer JE; Bisognano JD
    J Am Soc Hypertens; 2012; 6(2):152-8. PubMed ID: 22341199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension.
    Wallbach M; Lehnig LY; Schroer C; Lüders S; Böhning E; Müller GA; Wachter R; Koziolek MJ
    Hypertension; 2016 Apr; 67(4):701-9. PubMed ID: 26902491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.
    Hoppe UC; Brandt MC; Wachter R; Beige J; Rump LC; Kroon AA; Cates AW; Lovett EG; Haller H
    J Am Soc Hypertens; 2012; 6(4):270-6. PubMed ID: 22694986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension.
    Alnima T; Scheffers I; De Leeuw PW; Winkens B; Jongen-Vancraybex H; Tordoir JH; Schmidli J; Mohaupt MG; Allemann Y; Kroon AA
    J Hypertens; 2012 Aug; 30(8):1665-70. PubMed ID: 22728906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.
    Scheffers IJ; Kroon AA; Schmidli J; Jordan J; Tordoir JJ; Mohaupt MG; Luft FC; Haller H; Menne J; Engeli S; Ceral J; Eckert S; Erglis A; Narkiewicz K; Philipp T; de Leeuw PW
    J Am Coll Cardiol; 2010 Oct; 56(15):1254-8. PubMed ID: 20883933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial.
    Illig KA; Levy M; Sanchez L; Trachiotis GD; Shanley C; Irwin E; Pertile T; Kieval R; Cody R
    J Vasc Surg; 2006 Dec; 44(6):1213-1218. PubMed ID: 17145423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension.
    Tordoir JH; Scheffers I; Schmidli J; Savolainen H; Liebeskind U; Hansky B; Herold U; Irwin E; Kroon AA; de Leeuw P; Peters TK; Kieval R; Cody R
    Eur J Vasc Endovasc Surg; 2007 Apr; 33(4):414-21. PubMed ID: 17227715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].
    Wallbach M; Koziolek MJ; Wachter R
    Internist (Berl); 2018 Oct; 59(10):1011-1020. PubMed ID: 30182192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension.
    Alnima T; de Leeuw PW; Tan FE; Kroon AA;
    Hypertension; 2013 Jun; 61(6):1334-9. PubMed ID: 23589562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral or unilateral stimulation for baroreflex activation therapy.
    de Leeuw PW; Alnima T; Lovett E; Sica D; Bisognano J; Haller H; Kroon AA
    Hypertension; 2015 Jan; 65(1):187-92. PubMed ID: 25331845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems.
    Wachter R; Halbach M; Bakris GL; Bisognano JD; Haller H; Beige J; Kroon AA; Nadim MK; Lovett EG; Schafer JE; de Leeuw PW
    J Am Soc Hypertens; 2017 Feb; 11(2):81-91. PubMed ID: 28065708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of baroreflex activation therapy on blood pressure and sympathetic function in patients with refractory hypertension: the rationale and design of the Nordic BAT study.
    Gordin D; Fadl Elmula FEM; Andersson B; Gottsäter A; Elf J; Kahan T; Christensen KL; Vikatmaa P; Vikatmaa L; Bastholm Olesen T; Groop PH; Olsen MH; Tikkanen I;
    Blood Press; 2017 Oct; 26(5):294-302. PubMed ID: 28595464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension.
    Scheffers IJ; Kroon AA; Tordoir JH; de Leeuw PW
    Expert Rev Med Devices; 2008 Jan; 5(1):33-9. PubMed ID: 18095894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baroreflex activation therapy lowers arterial pressure without apparent stimulation of the carotid bodies.
    Alnima T; Goedhart EJ; Seelen R; van der Grinten CP; de Leeuw PW; Kroon AA
    Hypertension; 2015 Jun; 65(6):1217-22. PubMed ID: 25941348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheos: an implantable carotid sinus stimulation device for the nonpharmacologic treatment of resistant hypertension.
    Ng MM; Sica DA; Frishman WH
    Cardiol Rev; 2011; 19(2):52-7. PubMed ID: 21285662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension.
    Halbach M; Hickethier T; Madershahian N; Reuter H; Brandt MC; Hoppe UC; Müller-Ehmsen J
    J Hypertens; 2015 Aug; 33(8):1697-703. PubMed ID: 26107267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.